AC-262536
Also known as: AC262536, partial AR agonist AC-262
Partial androgen receptor agonist studied for neuroprotection in Alzheimer's models and anabolic tissue selectivity.
Quick Reference
AC-262536 - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemical compound
AC-262536, also known as Accadrine, is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the levator ani muscle weight increase of testosterone, but only around 27% of its maximal effect on prostate gland weight. It is an aniline SARM related to ACP-105 and vosilasarm (RAD140). The drug was encountered as a novel designer drug by at least 2020.
Mechanism of Action
AC-262536, also known as Accadrine, is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the levator ani muscle weight increase of testosterone, but only around 27% of its maximal effect on prostate gland weight. It is an aniline SARM related to ACP-105 and vosilasarm (RAD140). The drug was encountered as a novel designer drug by at least 2020.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
AC-262536 (also known as AC262536, partial AR agonist AC-262) is studied within the selective androgen receptor research community. Partial androgen receptor agonist studied for neuroprotection in Alzheimer's models and anabolic tissue selectivity.
Last updated October 28, 2026
Research status: limited. AC-262536 appears across selective androgen receptor research forums and academic literature. Researchers note this compound falls in the sarms category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with AC-262536. Comments are reviewed before appearing.